Core Viewpoint - The article discusses the fraudulent practices of Nohow Health, revealing how the company manipulated sales data and engaged in deceptive activities that led to its impending liquidation and delisting from the stock market [1][23]. Group 1: Fraudulent Practices - Nohow Health was accused of fabricating sales performance, with claims that 90% of its sales revenue was artificially inflated through various deceptive methods, including purchasing fecal samples from sanitation workers [4][8]. - The company utilized a network of third-party firms to facilitate these fraudulent transactions, creating a "virtual sale" environment where actual customer transactions were not necessary [9][11]. - The sales team expanded significantly, from about 100 employees in early 2021 to nearly 500 by 2022, which contributed to a 260% revenue increase, raising sales from 200 million to 760 million [12]. Group 2: Internal Knowledge and Accountability - Key executives, including the company's main leaders, were aware of and led the fraudulent activities, with only a select few high-ranking officials allowed to attend confidential sales strategy meetings [4][16]. - The company attempted to cover up its fraudulent activities by planning to falsify financial reports for 2024, which ultimately led to the withdrawal of Deloitte's audit support [4][18]. Group 3: Market Reaction and Consequences - Following the release of a short-selling report, Nohow Health's stock price plummeted from a peak of 38.95 HKD to 15.7 HKD, with trading volume surging to over 28 million shares on that day [18][19]. - The company is now undergoing a liquidation process, with the board of directors losing actual decision-making power, and the delisting appears inevitable [23]. Group 4: Investor Impact - Over 4,000 individual investors have registered to seek compensation, with total investments exceeding 700 million, highlighting the significant financial impact on public investors [24].
诺辉健康“造假”内幕